Global Osteosarcoma 麻豆原创 Research Report 2023

Publication ID:

PB502234030

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

An osteosarcoma (OS) is a cancerous tumor in a bone. Specifically, it is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid. Osteosarcoma is the most common histological form of primary bone cancer. It is most prevalent in teenagers and young adults.
Highlights
The global Osteosarcoma market was valued at US$ 551.3 million in 2022 and is anticipated to reach US$ 677.7 million by 2029, witnessing a CAGR of 3.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Osteosarcoma is the eighth-most common form of childhood cancer, comprising 2.4% of all malignancies in pediatric patients, and about 20% of all primary bone cancers. Incidence rates for osteosarcoma in U.S. patients under 20 years of age are estimated at 5.0 per million per year in the general population, with a slight variation between individuals of black, Hispanic, and white ethnicities (6.8, 6.5, and 4.6 per million per year, respectively). It is slightly more common in males (5.4 per million per year) than in females (4.0 per million per year).
Report Scope
This report aims to provide a comprehensive presentation of the global market for Osteosarcoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Osteosarcoma.
The Osteosarcoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Osteosarcoma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Osteosarcoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Spectrum Pharmaceuticals
Hikma Pharmaceuticals
Baxter
Isofol
Advaxis
Bellicum Pharmaceuticals
Novartis
Segment by Type
Intramedullary Osteosarcoma
Juxtacortical Osteosarcoma
Extraskeletal Osteosarcoma
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Osteosarcoma companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Osteosarcoma 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intramedullary Osteosarcoma
1.2.3 Juxtacortical Osteosarcoma
1.2.4 Extraskeletal Osteosarcoma
1.3 麻豆原创 by Application
1.3.1 Global Osteosarcoma 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Osteosarcoma 麻豆原创 Perspective (2018-2029)
2.2 Osteosarcoma Growth Trends by Region
2.2.1 Global Osteosarcoma 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Osteosarcoma Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Osteosarcoma Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Osteosarcoma 麻豆原创 Dynamics
2.3.1 Osteosarcoma Industry Trends
2.3.2 Osteosarcoma 麻豆原创 Drivers
2.3.3 Osteosarcoma 麻豆原创 Challenges
2.3.4 Osteosarcoma 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Osteosarcoma Players by Revenue
3.1.1 Global Top Osteosarcoma Players by Revenue (2018-2023)
3.1.2 Global Osteosarcoma Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Osteosarcoma 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Osteosarcoma Revenue
3.4 Global Osteosarcoma 麻豆原创 Concentration Ratio
3.4.1 Global Osteosarcoma 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Osteosarcoma Revenue in 2022
3.5 Osteosarcoma Key Players Head office and Area Served
3.6 Key Players Osteosarcoma Product Solution and Service
3.7 Date of Enter into Osteosarcoma 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Osteosarcoma Breakdown Data by Type
4.1 Global Osteosarcoma Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Osteosarcoma Forecasted 麻豆原创 Size by Type (2024-2029)
5 Osteosarcoma Breakdown Data by Application
5.1 Global Osteosarcoma Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Osteosarcoma Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Osteosarcoma 麻豆原创 Size (2018-2029)
6.2 North America Osteosarcoma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Osteosarcoma 麻豆原创 Size by Country (2018-2023)
6.4 North America Osteosarcoma 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Osteosarcoma 麻豆原创 Size (2018-2029)
7.2 Europe Osteosarcoma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Osteosarcoma 麻豆原创 Size by Country (2018-2023)
7.4 Europe Osteosarcoma 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Osteosarcoma 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Osteosarcoma 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Osteosarcoma 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Osteosarcoma 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Osteosarcoma 麻豆原创 Size (2018-2029)
9.2 Latin America Osteosarcoma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Osteosarcoma 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Osteosarcoma 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Osteosarcoma 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Osteosarcoma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Osteosarcoma 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Osteosarcoma 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Osteosarcoma Introduction
11.1.4 Pfizer Revenue in Osteosarcoma Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Spectrum Pharmaceuticals
11.2.1 Spectrum Pharmaceuticals Company Detail
11.2.2 Spectrum Pharmaceuticals Business Overview
11.2.3 Spectrum Pharmaceuticals Osteosarcoma Introduction
11.2.4 Spectrum Pharmaceuticals Revenue in Osteosarcoma Business (2018-2023)
11.2.5 Spectrum Pharmaceuticals Recent Development
11.3 Hikma Pharmaceuticals
11.3.1 Hikma Pharmaceuticals Company Detail
11.3.2 Hikma Pharmaceuticals Business Overview
11.3.3 Hikma Pharmaceuticals Osteosarcoma Introduction
11.3.4 Hikma Pharmaceuticals Revenue in Osteosarcoma Business (2018-2023)
11.3.5 Hikma Pharmaceuticals Recent Development
11.4 Baxter
11.4.1 Baxter Company Detail
11.4.2 Baxter Business Overview
11.4.3 Baxter Osteosarcoma Introduction
11.4.4 Baxter Revenue in Osteosarcoma Business (2018-2023)
11.4.5 Baxter Recent Development
11.5 Isofol
11.5.1 Isofol Company Detail
11.5.2 Isofol Business Overview
11.5.3 Isofol Osteosarcoma Introduction
11.5.4 Isofol Revenue in Osteosarcoma Business (2018-2023)
11.5.5 Isofol Recent Development
11.6 Advaxis
11.6.1 Advaxis Company Detail
11.6.2 Advaxis Business Overview
11.6.3 Advaxis Osteosarcoma Introduction
11.6.4 Advaxis Revenue in Osteosarcoma Business (2018-2023)
11.6.5 Advaxis Recent Development
11.7 Bellicum Pharmaceuticals
11.7.1 Bellicum Pharmaceuticals Company Detail
11.7.2 Bellicum Pharmaceuticals Business Overview
11.7.3 Bellicum Pharmaceuticals Osteosarcoma Introduction
11.7.4 Bellicum Pharmaceuticals Revenue in Osteosarcoma Business (2018-2023)
11.7.5 Bellicum Pharmaceuticals Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Osteosarcoma Introduction
11.8.4 Novartis Revenue in Osteosarcoma Business (2018-2023)
11.8.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Spectrum Pharmaceuticals
Hikma Pharmaceuticals
Baxter
Isofol
Advaxis
Bellicum Pharmaceuticals
Novartis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.